What it's for (Indications)
- Topical triamcinolone is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
- For formulations like Kenalog orabase (triamcinolone acetonide dental paste), it is specifically indicated for the temporary relief of symptoms associated with oral inflammatory and ulcerative lesions resulting from trauma.
- This includes conditions such as recurrent aphthous stomatitis (canker sores), lichen planus, and other inflammatory conditions of the oral mucosa that respond to corticosteroid therapy.
- It helps to reduce redness, swelling, itching, and discomfort associated with these conditions, promoting symptomatic relief and aiding in the healing process of non-infectious lesions.
- The therapeutic effect is localized, aiming to provide direct action at the site of inflammation, thereby alleviating pain and discomfort.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For topical triamcinolone preparations (creams, ointments, lotions), a thin film should be applied to the affected skin areas two to three times daily, or as directed by a healthcare professional. It is crucial to rub it in gently and completely to ensure adequate absorption. For oral formulations such as triamcinolone acetonide dental paste (e.g., Kenalog orabase), a small dab (about 1/4 inch) should be pressed onto the lesion until a thin film develops. This application should ideally be done at bedtime to allow the steroid to remain on the lesion for the longest possible duration. Depending on the severity of symptoms, it may be necessary to apply the preparation two or three times a day, preferably after meals. It is important not to rub the paste in, as this may cause it to crumble and fail to adhere to the mucosal surface. The duration of treatment should be limited and determined by the prescribing physician, generally not exceeding a few weeks for oral lesions unless under strict medical supervision due to the potential for local and systemic side effects. |
Safety & Warnings
Common Side Effects
- Local adverse reactions reported with topical corticosteroids include burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
- When applied to large surface areas, for prolonged periods, or under occlusive dressings, systemic absorption of corticosteroids can occur, leading to systemic side effects.
- These can include manifestations of Cushing's syndrome, hyperglycemia, and glycosuria.
- Adrenal suppression is a significant concern, especially in children, with symptoms such as linear growth retardation, delayed weight gain, low cortisol levels, and absence of response to ACTH stimulation.
- Oral paste formulations can also cause local irritation, taste disturbances, dry mouth, or, rarely, contribute to oral candidiasis due to localized immune suppression, which requires immediate medical attention if suspected.
Serious Warnings
- Black Box Warning: **SERIOUS WARNINGS: Potential for Systemic Absorption and HPA Axis Suppression** Topical triamcinolone, particularly with prolonged use, application to large surface areas, under occlusive dressings, or on compromised skin barriers, carries the potential for significant systemic absorption. This systemic absorption can lead to reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glycosuria. Patients, especially children, are at increased risk due to their larger skin surface area to body weight ratio and underdeveloped skin barrier function, making them more susceptible to systemic toxicity. HPA axis suppression may manifest as symptoms including fatigue, weakness, nausea, vomiting, hypotension, and dizziness. Regular monitoring for signs of HPA axis suppression is crucial, particularly in patients receiving long-term therapy or high doses. Discontinuation of the corticosteroid should be done gradually to avoid exacerbation of adrenal insufficiency. Use under the supervision of a healthcare professional is mandatory, and patients should be advised against exceeding prescribed dosages or durations of treatment. This warning emphasizes the importance of careful patient selection, appropriate application techniques, and vigilant monitoring to mitigate the risks associated with systemic corticosteroid effects, especially in vulnerable populations.
- Topical triamcinolone should be used with caution.
- Systemic absorption can lead to reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glycosuria.
- Factors increasing systemic absorption include the use of potent steroids, application to large surface areas, prolonged use, use under occlusive dressings, and application to thin or damaged skin.
- Patients should be periodically evaluated for HPA axis suppression, especially children, who may be more susceptible due to a larger skin surface area to body weight ratio.
- Pediatric patients may also exhibit linear growth retardation, delayed weight gain, and intracranial hypertension.
- Visual disturbances, such as blurred vision, cataracts, and glaucoma, have been reported with systemic and topical corticosteroid use.
- Avoid contact with eyes.
- Prolonged use may result in skin atrophy, striae, or telangiectasia.
- If irritation develops, discontinue use and institute appropriate therapy.
- The presence of infections at the treatment site may require concurrent antimicrobial therapy; if infection does not resolve, discontinue corticosteroid use to prevent exacerbation and spread.
How it Works (Mechanism of Action)
Triamcinolone is a synthetic corticosteroid that exerts its anti-inflammatory, antipruritic, and vasoconstrictive effects primarily through its action on glucocorticoid receptors. Upon penetrating the cell membrane, triamcinolone binds to specific cytoplasmic glucocorticoid receptors, forming a steroid-receptor complex. This complex then translocates into the cell nucleus, where it modulates gene transcription by binding to glucocorticoid response elements (GREs) on DNA. This modulation leads to the synthesis of anti-inflammatory proteins, such as lipocortins (annexins), which inhibit phospholipase A2, thereby preventing the synthesis of inflammatory mediators like prostaglandins and leukotrienes. Additionally, triamcinolone suppresses the migration of neutrophils and macrophages to the site of inflammation, reduces the release of lysosomal enzymes, and inhibits the effects of lymphokines. These combined actions result in a reduction of inflammation, pruritus, and vasoconstriction, providing symptomatic relief for various dermatological and oral mucosal conditions by dampening the immune response.